Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results

PASADENA, Calif. — December 20, 2011 — Arrowhead Research Corporation (NASDAQ: ARWRD), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth quarter and year ended September 30, 2011.

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors

PASADENA, Calif. — December 19, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S. Perry, Hon BSc, DVM, Ph.D., to its board of directors.

Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results

PASADENA, Calif., December 15, 2011--Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility

PASADENA, Calif. — November 23, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed David Lewis, Ph.D., as Vice President, Biology, and David Rozema, Ph.D., as Vice President, Chemistry, effective immediately.

Arrowhead Research Announces 1-for-10 Reverse Stock Split

PASADENA, Calif. — November 16, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the implementation of a 1-for-10 reverse stock split of its common stock. Trading on a post-split basis will begin November 17, 2011 at market open. The reverse stock split was proposed by the Company's Board of Directors and approved by Arrowhead stockholders at the 2011 Annual Meeting of Shareholders held on August 8, 2011.

Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund

HOUSTON, TX — November 14, 2011 — Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.

USA Today: "Experimental drug slims obese monkeys"

An experimental drug that targets and kills fat cells in the blood appears to help obese rhesus monkeys lose weight, a new study suggests.

Fox News: "Drug Kills Fat Cells in Obese Monkeys"

Obese monkeys saw their waistlines shrink in just weeks after scientists gave them an experimental drug that zaps fat cells, a study out today said, giving hope that such a pill for humans could be on the horizon.

Los Angeles Times: "Cancer treatment shows promise for rapid weight loss"

A synthetic peptide that inhibits blood supply, a strategy employed in many cancer drugs, is found to kill fat cells and improve metabolic function in trials involving monkeys.

CBS News: "Porky primates may help hefty humans slim down"

(CBS) What do skinny monkeys have to say about fighting flab in humans? Quite a lot, as it turns out.

Fox Business News: "Arrowhead Obesity Drug Shows Promise in Study"

Arrowhead Research (ARWR: 0.70, -0.05, -6.08%), which makes medicines in oncology and obesity based on nanotechnology, says its weight-loss drug has been performing well in a study involving obese monkeys.

Time: "Drug Based on Cancer Treatment Shows Promise for Weight Loss"

An experimental drug developed from cancer research showed early promise in a study of weight loss, researchers report, causing fat monkeys to shed an average 11% of their body weight after just a month of treatment.

Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys

PASADENA, Calif. — November 10, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of data from Ablaris Therapeutics, Inc.'s lead drug candidate, Adipotide™, demonstrating weight loss and reduction in body mass index and abdominal circumference in obese rhesus monkeys.

The Wall Street Journal: Drug Offers Hope in Obesity Fight

Treatment Targeting Fat Cells Caused Significant Weight Loss in Monkeys; Human Trials to Begin Soon

MSNBC: Drug helps 'couch potato' monkeys lose weight

A simple medication that leads to weight loss with no dieting or exercise could be a big step toward every dieter's dream. The study is only in monkeys, but tests in people could begin shortly.

Businessweek: Obese Monkeys Lose Weight as Drug Targets Blood Vessels in Fat

Nov. 9 (Bloomberg) -- Obese rhesus monkeys lost an average of 11 percent of their body weight on an experimental drug that cut off the blood supply to fat tissue, raising the possibility the treatment may work in humans, researchers said.

US News & World Report: Experimental Drug Slims Obese Monkeys

WEDNESDAY, Nov. 9 (HealthDay News) - An experimental drug that targets and kills fat cells in the blood appears to help obese rhesus monkeys lose weight, a new study suggests.

Science News: Novel Drug Shrinks Monkeys' Waistlines

More than 10 years ago, a husband-and-wife team came up with a novel way to fight disease: Look for small bits of protein that home in on specific tissues and attach a drug to them. Now, the work has brought the researchers close to a new therapy for obesity, which they report works well in monkeys and is edging toward human testing.

ABC News: New Drug Attacks Fat, Helps Obese Monkeys Slim Down

Scientists have developed a new drug that attacks excess body fat, and a new study reports that it helped a small group of obese monkeys lose weight. Experts say the drug's fat-attack mechanism is an intriguing approach to weight loss, but questions remain about the drug's effectiveness and safety in humans.

Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche

PASADENA, Calif. — November 7, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic polyconjugate (DPC) technology for safe and effective delivery of siRNA.

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

PASADENA, Calif. — November 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P. Rae, Ph.D., J.D., to the position of Chief Business Officer, effective November 1, 2011.

Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics

PASADENA, Calif. — November 2, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that a paper further validating the drug development programs of Ablaris Therapeutics, Inc., a subsidiary of Arrowhead, and Alvos Therapeutics, Inc., was published in the Proceedings of the National Academy of Sciences ("PNAS"), one of the world's most cited multidisciplinary journals covering the biological, physical, and social sciences.

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

PASADENA, Calif. — October 27, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.D. to the position of Chief Operating Officer of the Company effective October 26, 2011.

Blood Vessel Mapping Reveals Four New "ZIP Codes"

A research team led by scientists from The University of Texas MD Anderson Cancer Center have discovered four new "ZIP codes" in their quest to map the vast blood vessel network of the human body.

Arrowhead Research Corporation Acquires Roche RNA Assets and Site

PASADENA, Calif. – October 24, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has acquired RNA therapeutics assets from Roche (SIX: RO, ROG; OTCQX: RHHBY) including the state-of-the-art research site in Madison, WI.

Arrowhead Research Corporation Completes $5.5 Million Private Placement

PASADENA, Calif. - October 4, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that on September 30, 2011, it closed a private placement of approximately 14.5 million shares of common stock priced at market for $0.38 per share. Gross proceeds were approximately $5.5 million and will be used to fund current operations.

Arrowhead Reports Fiscal 2011 Third Quarter Financial Results

PASADENA, Calif. — August 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 third quarter ended June 30, 2011.

Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011

PASADENA, Calif. — August 1, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2011 third quarter ended June 30, 2011, on Monday, August 8, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board

PASADENA, Calif. – July 26, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that Timothy J. Triche, M.D., Ph.D., Professor of Pathology and Pediatrics at the University of Southern California ("USC") Keck School of Medicine, has agreed to join the Scientific Advisory Board ("SAB") of Arrowhead's majority owned subsidiary Calando Pharmaceuticals, Inc.

Arrowhead Research to Present at Two Nanomedicine-Focused Events in London

PASADENA, Calif. – June 21, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer Christopher Anzalone, Ph.D., will present at two upcoming nanomedicine-focused events at the Copthorne Tara Hotel in London.

New Stem Cell Research Could Aid in Battle Against Bulging Waistlines

HOUSTON, TX - June 16, 2011 - Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston (UTHealth) could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview

PASADENA, Calif. – June 16, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.D., was featured in a Medical Research, Diagnostic Substances & Life Science Tools Report published by The Wall Street Transcript.

Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement

PASADENA, Calif. – June 9, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on June 7, 2011, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until December 5, 2011 to regain compliance with NASDAQ's $1.00 minimum bid requirement.

Mauro Ferrari Honored by the Controlled Release Society

HOUSTON (May 17, 2011) - Mauro Ferrari, Ph.D. , president and CEO of The Methodist Hospital Research Institute in Houston, recently received the 2011 CRS Founders' Award. The prestigious, internationally-recognized Founders Award honors outstanding leaders in the field of bioactive material delivery science.

ARROWHEAD REPORTS FISCAL 2011 SECOND QUARTER FINANCIAL RESULTS

PASADENA, Calif. – May 12, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 second quarter ended March 31, 2011.

ARROWHEAD RESEARCH TO REPORT FISCAL 2011 SECOND QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON THURSDAY, MAY 12, 2011

PASADENA, Calif. — May 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that it will report its financial results for the fiscal 2011 second quarter ended March 31, 2011, on Thursday, May 12, 2011 at 4:30 p.m. Eastern time(1:30 p.m. Pacific time).

ARROWHEAD RESEARCH TO PRESENT AT THE 2011 MDB CAPITAL GROUP BRIGHT LIGHTS CONFERENCE ON MAY 10

PASADENA, Calif. — May 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 2011 MDB Capital Group Bright Lights Conference at 2:00 p.m. ET on Tuesday, May 10, 2011. The conference will feature over 40 of the most innovative companies with disruptive and market changing IP. The event is being held at the Le Parker Meridien Hotel in New York City.

ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD

PASADENA, Calif. — April 27, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J. Rossi, Ph.D., a pioneer and one of the world leaders in the field of RNAi discovery and development, has joined majority owned subsidiary Calando Pharmaceuticals, Inc. as a senior advisor. Dr. Rossi, who is also one of the co-founders of Calando, will be the first member of Calando's new Scientific Advisory Board.

ARROWHEAD RESEARCH INCREASES OWNERSHIP IN ABLARIS TO 64%

PASADENA, Calif. — April 6, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that majority-owned subsidiary Ablaris Therapeutics, Inc. has completed a second closing of its Series A financing round for gross proceeds of $1.2 million, with aggregate gross proceeds of $2.9 million to date.

Arrowhead Research to Present at the Roth Capital Partners 23^rd Annual OC Growth Stock Conference on March 16

PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the Roth 23rd Annual OC Growth Stock Conference at 11:30 a.m.

Arrowhead Reports Fiscal 2011 First Quarter Financial Results

PASADENA, Calif. – February 10, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 first quarter ended December 31, 2010.

Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference

PASADENA, Calif. — February 9, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO CEO & Investor Conference at 8:00 a.m. Eastern time on Monday, February 14, 2011 at the Waldorf-Astoria Hotel in New York City, New York. Dr. Anzalone will be discussing recent Company developments and its opportunities in nanomedicine.

Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011

PASADENA, Calif. — February 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that it will report its financial results for the fiscal 2011 first quarter ended December 31, 2010, on Thursday, February 10, 2011 after the market closes. Arrowhead management will host a conference call the same day to discuss those results and recent events at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals

PASADENA, Calif. – January 18, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) ("the Company") today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity.

Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront

PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company (KOSDAQ: 040670).

Molecular Healing

As seen in Fast Company, February 2011 issue

The article features Dr. Sam Stupp, founder of Nanotope, Inc., an Arrowhead portfolio company commercializing regenerative medicine technology developed by Dr. Stupp and his colleagues at Northwestern University. The article describes Dr. Stupp's interdisciplinary approach to technology development, marrying materials science and biology to promote healing of neural and other tissues.